RedC Biotech Overview
RedC Biotech is a pre-clinical, development stage company aiming at saving lives worldwide. RedC is developing a new, process, to create universal red blood cells from stem cells using a patented cultivation technology. It is a highly scalable process for production that can meet the global demand for safe red blood cell transfusions for anyone, anywhere. The universal red blood cells provided by RedC Biotech will be a blood type that is suitable for almost every patient and will have the same potency as the currently used red blood cell transfusion RedC Biotech collaborates with leading industry, academia and government organizations.
Cumulative Funding Raised Over Time ($)
Latest News
growth-positive
Israeli Company Produces Donor-Less Blood In Lab To Alleviate Shortages
Israeli company RedC Biotech is developing universal red blood cells in a lab to alleviate blood shortages. They aim to produce standardized mass production and scaling, making it easier and cheaper to produce and transport blood globally. RedC Biotech recently won the Aviram Awards- Tech for Humanity competition and received a grand prize of $500,000. The company plans to reduce the cost and infrastructure needs of blood transfusions, with a target cost of $50 per blood transfusion. The product is estimated to be available in about five years.
Customers
growth-positive
The startup aiming to make blood donations a thing of the past
Israeli startup RedC Biotech aims to generate an unlimited supply of universal red blood cells from a single donation of human stem cells. The companys goal is to allow blood donation agencies to be independent of the need for donors. RedC Biotech plans to produce and sell the blood like any other pharmaceutical product. The shortage of blood donations, especially in low-income countries and regions, has been exacerbated by the COVID-19 pandemic. RedC Biotechs technology would provide a solution by creating blood in a lab, ensuring uniform quality without pathogens and viruses. The company is currently in the process of scaling up production and aims to commercialize its product in the second half of the 2020s. RedC Biotech has raised $1.4 million in funding and is planning to build production facilities around the world.
Customers
growth-positive
ארי גרגיר מחברת Red-C Biotech הוא הזוכה בתחרות קרן זיו אבירם בדובאי כלכליסט
Ari Grigir, founder of Red-C Biotech, has won first place in the Aviram Awards - Tech for Humanity competition in Dubai. The company has developed a technology for producing universal red blood cells, which are vital for treating trauma, childbirth, surgeries, cancer, and various blood disorders. The company aims to produce RBC infusions at a cost of $50 per unit, without reliance on donors and volunteers. The competition seeks to identify projects that change reality in the Middle East.
CustomersPartners
רד סי המנצחת הגדולה של תחרות הסטארט-אפ של ישראל
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $3M |
| Last funding | $1.1M |
| Stage | Pre-Seed |
| Rounds | 4 |
| Investors | 1 |
Team Members
1
Employees: 1-10
Web & Social Links
| Website | www.redcbiotech.com |
Locations
Bnei Zion, Israel
Photos & Videos
2 item(s)